Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +26.23%
#6 Humanity Humanity +24.52%
#7 Enso Enso +17.44%
#8 Codatta Codatta +16.38%
#9 Velvet Velvet +15.00%
#10 Tutorial Tutorial +14.47%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rank in Stocks #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Share Price
$0.07600875
Last synced: 2024-11-20
Market Cap
$2.06M
Change (1 day)
-0.51%
Change (1 year)
0.00%
Country
FR
Trade Quantum Genomics S.A. (ALQGC)

Category

Healthcare
Earnings for Quantum Genomics S.A. (ALQGC)
Earnings in Dec 2024 TTM: $-9.25M
According to Quantum Genomics S.A. latest financial reports the company's current earnings are $-9.25M. In 2023 the company made an earning of $-3.54M, an increase over its 2022 earnings that were of $-29.48M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Quantum Genomics S.A. from 2009 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-9.25M 0.00%
2024 $-9.25M 161.14%
2023 $-3.54M -87.98%
2022 $-29.48M 30.61%
2021 $-22.57M 1.34%
2020 $-22.27M 86.84%
2019 $-11.92M -22.86%
2018 $-15.45M 22.30%
2017 $-12.64M 93.73%
2016 $-6.52M 34.15%
2015 $-4.86M 58.10%
2014 $-3.08M 16.82%
2013 $-2.63M 85.17%
2012 $-1.42M 5.32%
2011 $-1.35M -26.18%
2010 $-1.83M -13.18%
2009 $-2.11M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -57,102.94%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -21,179.60%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -32,581.13%
BE